Hosted on MSN

MTVA: Phase 1 part 3 16-week titration study of DA-1726 to initiate in April 2026

Phase 1 Part 3 Trial of DA-1726 to Initiate in April 2026 On March 18, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the approval of the clinical trial plan by the Institutional Review Board (IRB) at ...
Monthly Prescribing Reference

Study Shows Modified Donanemab Titration Regimen Cuts Risk of ARIA-E

Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
Yahoo Finance

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ --MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled ...
Yahoo Finance

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

MetaVia, Inc. (NASDAQ: MTVA) is currently conducting Part 3 of the Phase 1 study of DA-1726, the company's oxyntomodulin analog agonist that targets glucagon-like peptide-1 receptors (GLP1R) and ...
Hosted on MSN

MTVA: Dose titration complete in phase 1 part 3 study of DA-1726

Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 MetaVia, Inc. (NASDAQ: MTVA) is currently conducting Part 3 of the Phase 1 study of DA-1726, the company’s oxyntomodulin analog agonist that ...